Progress and Priorities in Systemic Sclerosis: The Next 10 Years – Report from the World Scleroderma Foundation

Abstract

Get full access to this article

View all access options for this article.

References

Montani

Chaumais

Guignabert

et al. Targeted therapies in pulmonary arterial hypertension. Pharmacol Ther 2014;141(2)172–91

Matucci-Cerinic

Denton

Furst

et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 2011;70(1)32–38

Tashkin

Elashoff

Clements

et al; Scleroderma Lung Study Research Group. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006;354(25)2655–2666

van Laar

Farge

Sont

et al; EBMT/EULAR Scleroderma Study Group. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 2014;311(24):2490–2498

Naraghi

van Laar

Update on stem cell transplantation for systemic sclerosis: recent trial results. Curr Rheumatol Rep 2013;15(5)326

Kowal-Bielecka

Landewé

Avouac

et al; EUSTAR Co-Authors. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2009;68(5)620–628

Khanna

Walker

Mueller-Ladner

et al. Twenty-two points to consider for clinical trials in systemic sclerosis, based on EULAR standards. Rheumatology (Oxford) 2015;54(1)144–151

Thombs

Jewett

Assassi

et al. New directions for patient-centred care in scleroderma: the Scleroderma Patient-centred Intervention Network (SPIN). Clin Exp Rheumatol 2012;30(2 Suppl 71)S23–S29

Khanna

Brown

Clements

et al. Systemic sclerosis-associated interstitial lung disease-proposed recommendations for future randomized clinical trials. Clin Exp Rheumatol 2010;28(2 Suppl 58)S55–S62

10.

Merkel

Silliman

Clements

et al. Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse scleroderma. Arthritis Rheum 2012;64(10)3420–9